Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia Pharmaceuticals Inc. is set to engage with investors through one-on-one meetings at two key healthcare conferences in July 2024, showcasing their commitment to addressing autoimmune diseases with groundbreaking therapies like their FDA-approved LUPKYNIS for lupus nephritis. The company’s global development efforts are anchored by their Canadian headquarters and their U.S. commercial office.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
